| 0.016 0 (0%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
LumiraDx Limited is a prominent provider of point-of-care diagnostic solutions. Its core mission is to revolutionize community healthcare by equipping medical professionals with crucial diagnostic insights directly at the patient's side. The company develops and commercializes a sophisticated diagnostic platform, offering a diverse array of tests that deliver laboratory-grade performance directly at the point of care. With approximately 30 tests either commercially available or under development, their comprehensive portfolio addresses critical conditions such as infectious diseases, cardiovascular disorders, diabetes, and coagulation issues. Furthermore, they offer a full suite of COVID-19 testing solutions, adaptable for both laboratory environments and immediate point-of-need applications. These diagnostic tools are widely adopted by governments and healthcare institutions, deployed in diverse settings including traditional laboratories, urgent care clinics, physician's offices, pharmacies, schools, and workplaces. Their applications span screening, diagnosis, and monitoring for both general wellness and specific diseases. Established in 2014, the company's headquarters are located in London, United Kingdom.
Thu, 31 Jul 2025
LUMIRADX LTD C/WTS 28/09/2026 (TO PUR COM) (LMDXW) Stock Forum and Discussion - Moomoo
Tue, 24 Sep 2024
LumiraDx Limited (NASDAQ: LMDX) - Share Price - intelligentinvestor.com.au
Mon, 08 Jan 2024
Why Is LumiraDx (LMDX) Stock Down 13% Today? - InvestorPlace
Fri, 05 Jan 2024
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th - Yahoo Finance
Fri, 29 Dec 2023
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche - Yahoo Finance
Wed, 20 Oct 2021
LumiraDx receives approval for its COVID-19 Antigen Test for use in India - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|